the Circle. · CGTI 2027 · Berlin
Uwe Gottschalk · Conference Chair · Operating Partner, Keensight Capital
What delivers.
What sustains.
Who reaches the patient.
The pathway that holds. The infrastructure between vector and patient is being built.
Less noise. More signal.
01
Every cell and gene therapy leader carries the same weight. How does clinical proof become patient access at scale. The pathway that holds. The infrastructure between vector and patient is still being built.
02
The white space is the room that holds the conversation differently. Closed-door. By invitation. End-user led. No expo hall. No vendor pitch. A circle for the leaders closing the gap between science and the patient who cannot wait.
03
the Conversation. CGTI is that room. Senior cell and gene therapy leadership convened around the work that compounds. Vector manufacturing. Process intensification. CDMO strategy. Regulatory submission. Less noise. More signal.
04
Who attends. Senior faculty drawn from the leaders who own the programme, sign the batch record and carry the accountability. Announced in cadence with the programme.
Cell & Gene Therapy Innovation 2027
For decision makers from small biotech to global pharma. For the patients. We must do better.
The gap.
Cell and gene therapy moves faster than the infrastructure designed to deliver it. Vector manufacturing capacity is still the bottleneck. The compliance gap between model output and patient accountability has never been formally closed. The leaders who carry that accountability have not had the room they need.
The Conversation.
CGTI convenes the leaders building the infrastructure that closes that gap · across viral vector manufacturing · cell therapy process development · CDMO strategy · regulatory strategy and patient access. The corridor where CGT ambition becomes clinical supply · or breaks. The Conversation is where the leaders who carry the accountability meet before the patient does.
The decision.
What delivers. What sustains. Who reaches the patient. Three questions the room must hold before the process locks. For the leaders who own the programme, sign the batch record and are accountable for the gap no one has formally closed.
Uwe Gottschalk
Conference Chair · Operating Partner, Keensight Capital
Faculty announced in cadence with the programme.
The room.
Cell & Gene Therapy Innovation · Berlin · 2027
"
Not a conference. A room where the work compounds.
Uwe Gottschalk · Conference Chair · CGTI 2027
the circle. forum · in the room
cgti.ai · the years before · by GBX Circle
in the room · CGTI
the room · GBX Circle
the conversation · CGTI
in the room · CGTI
the room assembled · CGTIBy invitation. By relevance. By room.
Up to
150
senior leaders
Ratio
80/20
end-user · partner
Format
Two
days
closed-door
By invitation. By relevance. By room.
The leaders who own the programme, sign the batch record and carry the accountability for what reaches the patient.
Pharma · Biotech · CDMO · Academic Medical
CGTI 2027 · Berlin.
Who attends.
Key partners · confirmed
the circle. · access
The prospectus is not public. Shared directly with the organisations that belong. Who attends.
"Not a conference. A room where the work compounds."
Uwe Gottschalk · Conference Chair · CGTI 2027
The room. The conversations. The decisions.
A note on privacy.
This site uses essential cookies to function. We optionally use analytics to understand how the site is used. Nothing is shared. Nothing is sold.